CHA
ADAP

Carmichael Hill & Associates’s Adaptimmune Therapeutics ADAP Stock Holding History

Carmichael Hill & Associates’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$499 Hold
525
– – ﹤0.01% 753
2024
Q2 		$512 Hold
525
– – ﹤0.01% 749
2024
Q1 		$830 Hold
525
– – ﹤0.01% 725
2023
Q4 		$417 Hold
525
– – ﹤0.01% 765
2023
Q3 		$410 Hold
525
– – ﹤0.01% 763
2023
Q2 		$486 Hold
525
– – ﹤0.01% 758
2023
Q1 		$573 Hold
525
– – ﹤0.01% 748
2022
Q4 		$766 Hold
525
– – ﹤0.01% 735
2022
Q3 		$1K Hold
525
– – ﹤0.01% 756
2022
Q2 		$1K Hold
525
– – ﹤0.01% 741
2022
Q1 		$1K Buy
525
+175
+50% +$472 ﹤0.01% 761
2021
Q4 		$1K Buy
350
+140
+67% +$637 ﹤0.01% 770
2021
Q3 		$1K Hold
210
– – ﹤0.01% 762
2021
Q2 		$1K Buy
210
+90
+75% +$437 ﹤0.01% 748
2021
Q1 		$1K Hold
120
– – ﹤0.01% 729
2020
Q4 		$1K Buy
120
+80
+200% +$435 ﹤0.01% 700
2020
Q3 		$0 Buy
+40
New +$350 ﹤0.01% 712

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Carmichael Hill & Associates's ADAP Position: Q3 2024 in Review

Carmichael Hill & Associates held its Adaptimmune Therapeutics (ADAP) position steady in Q3 2024 at 525 shares worth $499. The position accounts for ﹤0.01% of the portfolio, ranked #753.

Carmichael Hill & Associates first reported a position in ADAP in Q3 2020 and has held it in 17 quarters since. The position peaked at $1K in Q3 2022. 81 funds tracked by Wall St. Rank hold ADAP as of Q3 2024.

  • Carmichael Hill & Associates held 525 shares of Adaptimmune Therapeutics worth $499 as of Q3 2024.
  • Carmichael Hill & Associates left its Adaptimmune Therapeutics share count unchanged in Q3 2024.
  • Adaptimmune Therapeutics made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #753 holding.
  • Carmichael Hill & Associates first reported a position in Adaptimmune Therapeutics in Q3 2020 and has held it in 17 quarters since.
  • Carmichael Hill & Associates's Adaptimmune Therapeutics position peaked at $1K in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.